DermaSensor develops an FDA-cleared, AI-powered medical device that helps physicians assess suspicious skin lesions and detect skin cancer at the point of care. Using Elastic Scattering Spectroscopy (ESS) alongside artificial intelligence, the non-invasive device analyzes lesions and provides a prompt, objective risk assessment. It supports evaluation for the three most common skin cancers: melanoma, basal cell carcinoma, and squamous cell carcinoma. The company reports 96% sensitivity across these cancers and a 52% reduction in missed cancer referrals, based on cited clinical evidence.

Designed for use during routine patient visits, DermaSensor serves primary care practices, health systems, specialty care providers, and value-based care organizations. Its services include device demonstrations, product education, clinical integration resources, research and evidence materials, and reimbursement guidance. Providers can access certified coding support, help navigating payer requirements, documentation guidance, and individualized assistance through a reimbursement hotline. Each device includes a charging dock, power supply, and regional adapter blades; the company also offers training tools and on-demand customer support.